Bristol-Myers Squibb buys Mirati in $5.8 billion deal
Bristol-Myers Squibb said it will acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade.
Business
• 09 Oct 23
